Cover Image
市場調查報告書

IMMUNOMEDICS, INC - 產品平台分析

Immunomedics Inc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224583
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
IMMUNOMEDICS, INC - 產品平台分析 Immunomedics Inc - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 89 Pages
簡介

Immunomedics, Inc.是生物製藥公司,開發治療癌症及自體免疫疾病等嚴重疾病用單株抗體產品。並藉由開發新生物醫藥品擴大業績。

本報告提供Immunomedics, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Immunomedics, Inc.的基本資料

Immunomedics, Inc.概要

  • 主要資訊
  • 企業資料

Immunomedics, Inc.:R&D概要

  • 主要的治療範圍

Immunomedics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Immunomedics, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Immunomedics, Inc.:藥物簡介

  • epratuzumab
  • yttrium Y 90 clivatuzumab tetraxetan
  • IMMU-130
  • IMMU-132
  • veltuzumab
  • IMMU-110
  • milatuzumab
  • TF-2
  • IMMU-114
  • 1R-(15)-(15)
  • 1R-(E1)-(E1)
  • Interferon Lambda-1 Linked Fab Dimer
  • TF-12
  • hA19 Antibody

Immunomedics, Inc.:開發平台分析

  • 各治療分類
  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Immunomedics, Inc.:最近的開發平台趨勢

Immunomedics, Inc.:暫停中的計劃

Immunomedics, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • veltuzumab
  • ■Immunomedics, Inc.:企業發表

Immunomedics, Inc.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08188CDB

Summary

Global Markets Direct's, 'Immunomedics Inc - Product Pipeline Review - 2016', provides an overview of the Immunomedics Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc
  • The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immunomedics Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immunomedics Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immunomedics Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immunomedics Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunomedics Inc Snapshot
    • Immunomedics Inc Overview
    • Key Facts
  • Immunomedics Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Immunomedics Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Immunomedics Inc - Pipeline Products Glance
    • Immunomedics Inc - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Immunomedics Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immunomedics Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Immunomedics Inc - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Immunomedics Inc - Drug Profiles
    • 14-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 15-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 19-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-15-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1R-E1-E1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 20-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 202-b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C2-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E1-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epratuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hex-hR1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMMU-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • labetuzumab govitecan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M1-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • milatuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD19 for B-Cell Hematologic Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CEACAM6 for Colon Cancer and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monocloncal Antibody to Target CD-19 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sacituzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yttrium Y 90 epratuzumab tetraxetan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Immunomedics Inc - Pipeline Analysis
    • Immunomedics Inc - Pipeline Products by Target
    • Immunomedics Inc - Pipeline Products by Route of Administration
    • Immunomedics Inc - Pipeline Products by Molecule Type
    • Immunomedics Inc - Pipeline Products by Mechanism of Action
  • Immunomedics Inc - Dormant Projects
  • Immunomedics Inc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • clivatuzumab tetraxetan
      • epratuzumab
      • ImmuRAIT-LL2
      • veltuzumab
  • Immunomedics Inc - Company Statement
  • Immunomedics Inc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunomedics Inc, Key Facts
  • Immunomedics Inc - Pipeline by Indication, 2016
  • Immunomedics Inc - Pipeline by Stage of Development, 2016
  • Immunomedics Inc - Monotherapy Products in Pipeline, 2016
  • Immunomedics Inc - Partnered Products in Pipeline, 2016
  • Immunomedics Inc - Partnered Products/ Combination Treatment Modalities, 2016
  • Immunomedics Inc - Phase III, 2016
  • Immunomedics Inc - Phase II, 2016
  • Immunomedics Inc - Phase I, 2016
  • Immunomedics Inc - Preclinical, 2016
  • Immunomedics Inc - Discovery, 2016
  • Immunomedics Inc - Unknown, 2016
  • Immunomedics Inc - Pipeline by Target, 2016
  • Immunomedics Inc - Pipeline by Route of Administration, 2016
  • Immunomedics Inc - Pipeline by Molecule Type, 2016
  • Immunomedics Inc - Pipeline Products by Mechanism of Action, 2016
  • Immunomedics Inc - Dormant Developmental Projects,2016
  • Immunomedics Inc - Discontinued Pipeline Products, 2016
  • Immunomedics Inc, Other Locations
  • Immunomedics Inc, Subsidiaries

List of Figures

  • Immunomedics Inc - Pipeline by Top 10 Indication, 2016
  • Immunomedics Inc - Pipeline by Stage of Development, 2016
  • Immunomedics Inc - Monotherapy Products in Pipeline, 2016
  • Immunomedics Inc - Pipeline by Top 10 Target, 2016
  • Immunomedics Inc - Pipeline by Route of Administration, 2016
  • Immunomedics Inc - Pipeline by Molecule Type, 2016
  • Immunomedics Inc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top